Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments.


Journal

Nature cell biology
ISSN: 1476-4679
Titre abrégé: Nat Cell Biol
Pays: England
ID NLM: 100890575

Informations de publication

Date de publication:
07 2019
Historique:
received: 10 04 2018
accepted: 22 05 2019
entrez: 3 7 2019
pubmed: 3 7 2019
medline: 27 11 2019
Statut: ppublish

Résumé

Most human tumours are heterogeneous, composed of cellular clones with different properties present at variable frequencies. Highly heterogeneous tumours have poor clinical outcomes, yet the underlying mechanism remains poorly understood. Here, we show that minor subclones of breast cancer cells expressing IL11 and FIGF (VEGFD) cooperate to promote metastatic progression and generate polyclonal metastases composed of driver and neutral subclones. Expression profiling of the epithelial and stromal compartments of monoclonal and polyclonal primary and metastatic lesions revealed that this cooperation is indirect, mediated through the local and systemic microenvironments. We identified neutrophils as a leukocyte population stimulated by the IL11-expressing minor subclone and showed that the depletion of neutrophils prevents metastatic outgrowth. Single-cell RNA-seq of CD45

Identifiants

pubmed: 31263265
doi: 10.1038/s41556-019-0346-x
pii: 10.1038/s41556-019-0346-x
pmc: PMC6609451
mid: EMS83263
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

879-888

Subventions

Organisme : Swiss National Science Foundation
ID : 175139
Pays : Switzerland
Organisme : NCI NIH HHS
ID : T32 CA207021
Pays : United States

Références

Nat Cell Biol. 2018 Sep;20(9):1084-1097
pubmed: 30154549
Cancer Discov. 2015 Nov;5(11):1164-1177
pubmed: 26410082
Drug Discov Today. 2005 May 1;10(9):653-62
pubmed: 15894230
Oncoimmunology. 2017 Jun 19;6(8):e1334744
pubmed: 28919995
Cancer Res. 2001 Sep 15;61(18):6649-55
pubmed: 11559528
J Leukoc Biol. 2008 Jan;83(1):64-70
pubmed: 17884993
Nat Rev Immunol. 2015 Nov;15(11):669-82
pubmed: 26471778
Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):594-9
pubmed: 23267071
Mol Cancer Ther. 2015 Jun;14(6):1385-94
pubmed: 25887886
J Clin Invest. 2013 Apr;123(4):1615-29
pubmed: 23549086
Nature. 2015 Jun 18;522(7556):345-348
pubmed: 25822788
Cancer Cell. 2017 Aug 14;32(2):169-184.e7
pubmed: 28810143
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Biotechnol. 2015 May;33(5):495-502
pubmed: 25867923
Bioinformatics. 2012 Aug 15;28(16):2184-5
pubmed: 22743226
PLoS Med. 2016 Dec 6;13(12):e1002174
pubmed: 27923045
Science. 2000 Aug 18;289(5482):1197-202
pubmed: 10947988
Mol Immunol. 2019 Jun;110:69-76
pubmed: 29269005
Nat Commun. 2013;4:1393
pubmed: 23340433
Nature. 2014 Oct 2;514(7520):54-8
pubmed: 25079331
Bioinformatics. 2017 Jul 15;33(14):2221-2223
pubmed: 28334409
Development. 2017 Feb 1;144(3):507-518
pubmed: 28087639
Nat Cell Biol. 2014 Aug;16(8):717-27
pubmed: 25082194
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Nature. 2015 Jun 18;522(7556):349-53
pubmed: 25985180
Cell. 2012 Jan 20;148(1-2):362-75
pubmed: 22265421
Cancers (Basel). 2010 Mar 30;2(2):305-37
pubmed: 24281072
Ann Surg Oncol. 2006 Jun;13(6):802-8
pubmed: 16614887
Cancer Cell. 2018 Feb 12;33(2):173-186.e5
pubmed: 29438694
J Pathol. 2007 Sep;213(1):56-64
pubmed: 17674348
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Oncotarget. 2017 Jan 24;8(4):6652-6662
pubmed: 28036264
Cell. 2014 Feb 13;156(4):649-62
pubmed: 24486105
Nature. 2015 Dec 17;528(7582):413-7
pubmed: 26649828
Nat Immunol. 2016 Sep 20;17(10):1142-9
pubmed: 27648547
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nat Immunol. 2008 Oct;9(10):1091-4
pubmed: 18800157
J Clin Invest. 2018 Apr 2;128(4):1371-1383
pubmed: 29480819
Tumour Biol. 2016 Jan;37(1):361-8
pubmed: 26219894
Cancer Cell. 2003 Jun;3(6):537-49
pubmed: 12842083
Cancer Cell. 2011 Sep 13;20(3):300-14
pubmed: 21907922
Trends Cancer. 2016 May;2(5):263-276
pubmed: 28741512
Cancer Res. 2017 Apr 1;77(7):1548-1552
pubmed: 28330928
Cancer Cell. 2013 Aug 12;24(2):257-71
pubmed: 23948300
Nat Rev Cancer. 2012 Apr 19;12(5):323-34
pubmed: 22513401
Clin Cancer Res. 2014 Nov 15;20(22):5579-88
pubmed: 25074610
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905

Auteurs

Michalina Janiszewska (M)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.
Department of Molecular Medicine, The Scripps Research Institute, Jupiter, FL, USA.

Doris P Tabassum (DP)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Research Square, Durham, NC, USA.

Zafira Castaño (Z)

Department of Medicine, Harvard Medical School, Boston, MA, USA.
Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Simona Cristea (S)

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.

Kimiyo N Yamamoto (KN)

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.

Natalie L Kingston (NL)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Katherine C Murphy (KC)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Shaokun Shu (S)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.

Nicholas W Harper (NW)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Carlos Gil Del Alcazar (CG)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.

Maša Alečković (M)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.

Muhammad B Ekram (MB)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.
WuXi NextCODE, Cambridge, MA, USA.

Ofir Cohen (O)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Minsuk Kwak (M)

Department of Biomedical Engineering, Yale School of Medicine, New Haven, CT, USA.
Yale Comprehensive Cancer Center, New Haven, CT, USA.

Yuanbo Qin (Y)

Department of Medicine, Harvard Medical School, Boston, MA, USA.
Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
EdiGene, Cambridge, MA, USA.

Tyler Laszewski (T)

Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Adrienne Luoma (A)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, and Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA.

Andriy Marusyk (A)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.
Department of Cancer Imaging and Metabolism, Moffitt Cancer Center, Tampa, FL, USA.

Kai W Wucherpfennig (KW)

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, and Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA.

Nikhil Wagle (N)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Rong Fan (R)

Department of Biomedical Engineering, Yale School of Medicine, New Haven, CT, USA.
Yale Comprehensive Cancer Center, New Haven, CT, USA.

Franziska Michor (F)

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA.
Ludwig Center at Harvard, Boston, MA, USA.

Sandra S McAllister (SS)

Department of Medicine, Harvard Medical School, Boston, MA, USA.
Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Harvard Stem Cell Institute, Cambridge, MA, USA.

Kornelia Polyak (K)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.
Department of Medicine, Harvard Medical School, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.
The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA. kornelia_polyak@dfci.harvard.edu.
Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.
Ludwig Center at Harvard, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.
Harvard Stem Cell Institute, Cambridge, MA, USA. kornelia_polyak@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH